Pharming Group N.V. (AMS: PHARM)
Netherlands
· Delayed Price · Currency is EUR 0.716
+0.021 (3.02%)
Nov 22, 2024, 5:35 PM CET
Pharming Group Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Jan '20 Jan 1, 2020 | 2019 - 2015 |
| Revenue | 285.75 | 245.32 | 205.62 | 198.87 | 212.17 | 189.39 | Upgrade
|
| Revenue Growth (YoY) | 30.64% | 19.30% | 3.39% | -6.27% | 12.03% | 40.15% | Upgrade
|
| Cost of Revenue | 30.3 | 25.21 | 17.56 | 21.14 | 23.54 | 23.93 | Upgrade
|
| Gross Profit | 255.44 | 220.1 | 188.06 | 177.73 | 188.64 | 165.46 | Upgrade
|
| Selling, General & Admin | 195.14 | 175.26 | 127.44 | 90.97 | 75.69 | 65.92 | Upgrade
|
| Research & Development | 72.21 | 68.66 | 52.53 | 65.38 | 38.52 | 32.61 | Upgrade
|
| Other Operating Expenses | -2.39 | -2.07 | -2.28 | -2.62 | -1.83 | -0.49 | Upgrade
|
| Operating Expenses | 264.96 | 241.85 | 177.69 | 153.73 | 112.38 | 98.04 | Upgrade
|
| Operating Income | -9.52 | -21.75 | 10.37 | 24 | 76.26 | 67.43 | Upgrade
|
| Interest Expense | -8.83 | -5.96 | -5.36 | -6.09 | -5.94 | -13.35 | Upgrade
|
| Interest & Investment Income | 5.37 | 3.66 | 0.09 | 0.05 | 0.72 | 1.13 | Upgrade
|
| Earnings From Equity Investments | -0.61 | -0.29 | -1.08 | 0.69 | 0.36 | 0.26 | Upgrade
|
| Currency Exchange Gain (Loss) | -2.97 | -2.97 | 4.4 | 14.84 | -19.23 | -0.52 | Upgrade
|
| Other Non Operating Income (Expenses) | 5.03 | -0.13 | -0.11 | -0.09 | -0.07 | -0.23 | Upgrade
|
| EBT Excluding Unusual Items | -11.53 | -27.45 | 8.31 | 33.4 | 52.08 | 54.71 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.93 | -0.93 | 11.06 | 0.11 | 0.07 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.18 | 21.28 | - | - | - | - | Upgrade
|
| Asset Writedown | -4.92 | -4.92 | -4.38 | -10.44 | - | 0.82 | Upgrade
|
| Other Unusual Items | - | - | - | - | -8.06 | -3.23 | Upgrade
|
| Pretax Income | -17.2 | -12.01 | 14.99 | 23.08 | 44.09 | 52.3 | Upgrade
|
| Income Tax Expense | 0.62 | -1.46 | 1.31 | 7.08 | 6.35 | 11.75 | Upgrade
|
| Net Income | -17.82 | -10.55 | 13.67 | 16 | 37.75 | 40.56 | Upgrade
|
| Net Income to Common | -17.82 | -10.55 | 13.67 | 16 | 37.75 | 40.56 | Upgrade
|
| Net Income Growth | - | - | -14.52% | -57.62% | -6.93% | 62.27% | Upgrade
|
| Shares Outstanding (Basic) | 652 | 657 | 649 | 642 | 636 | 626 | Upgrade
|
| Shares Outstanding (Diluted) | 652 | 657 | 707 | 701 | 683 | 674 | Upgrade
|
| Shares Change (YoY) | -1.41% | -7.09% | 0.85% | 2.70% | 1.37% | 3.06% | Upgrade
|
| EPS (Basic) | -0.03 | -0.02 | 0.02 | 0.02 | 0.06 | 0.06 | Upgrade
|
| EPS (Diluted) | -0.03 | -0.02 | 0.02 | 0.02 | 0.05 | 0.06 | Upgrade
|
| EPS Growth | - | - | -17.39% | -58.18% | -9.84% | 60.53% | Upgrade
|
| Free Cash Flow | -0.51 | -18.74 | 21.08 | 27.1 | 78.97 | 71.5 | Upgrade
|
| Free Cash Flow Per Share | -0.00 | -0.03 | 0.03 | 0.04 | 0.12 | 0.11 | Upgrade
|
| Gross Margin | 89.39% | 89.72% | 91.46% | 89.37% | 88.91% | 87.37% | Upgrade
|
| Operating Margin | -3.33% | -8.87% | 5.04% | 12.07% | 35.94% | 35.60% | Upgrade
|
| Profit Margin | -6.24% | -4.30% | 6.65% | 8.04% | 17.79% | 21.41% | Upgrade
|
| Free Cash Flow Margin | -0.18% | -7.64% | 10.25% | 13.63% | 37.22% | 37.75% | Upgrade
|
| EBITDA | -3.06 | -15.29 | 15.89 | 30.39 | 82.54 | 72.42 | Upgrade
|
| EBITDA Margin | -1.07% | -6.23% | 7.73% | 15.28% | 38.90% | 38.24% | Upgrade
|
| D&A For EBITDA | 6.46 | 6.46 | 5.53 | 6.39 | 6.29 | 4.99 | Upgrade
|
| EBIT | -9.52 | -21.75 | 10.37 | 24 | 76.26 | 67.43 | Upgrade
|
| EBIT Margin | -3.33% | -8.87% | 5.04% | 12.07% | 35.94% | 35.60% | Upgrade
|
| Effective Tax Rate | - | - | 8.76% | 30.69% | 14.40% | 22.46% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.